Please try another search
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Alan R. Williamson | 87 | 2016 | Chairman of Scientific Advisory Board |
Jack E. Stover | 71 | 2016 | Independent Director |
Werner Cautreels | 72 | 2024 | CEO & Director |
Nikolay Savchuk | - | 2024 | COO & Director |
Iain D. Dukes | 66 | 2024 | Executive Chairman |
Mary Theresa Shoemaker | 62 | 2020 | Independent Director |
George F. Vande Woude | - | - | Member of Scientific Advisory Board |
Stephen D. Nimer | 69 | 2005 | Member of Scientific Advisory Board |
David Ross Parkinson | 74 | - | Member of Scientific Advisory Board |
Anna Marie Skalka | - | - | Member of Scientific Advisory Board |
James J. Marino | 74 | 2015 | Independent Director |
Ross C. Donehower | - | - | Member of Scientific Advisory Board |
Trafford Clarke | 65 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review